Healthcare / BiotechnologyNasdaqCM
$2.46
-0.17 (-6.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $31.3M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$233M
P/E
6.5x
↓EV/EBITDA
4.5x
↓ROE
34.4%
↑Gross Margin
87.3%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+113.3%
FCF CAGR
—
FCF margin
43.1%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $72.8M · net income $35.3M · FCF $31.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $72.8M | $72.8M | $27.9M | $33.5M | $7.5M |
| Net Income | $35.3M | $35.3M | $-14.2M | $-18.8M | $-33.7M |
| EBITDA | $31.8M | $31.8M | $-14.4M | $-12.5M | $-34.9M |
| EPS | 0.38 | 0.38 | -0.16 | -0.21 | -0.39 |
| Gross Margin | 87.3% | 87.3% | 71.5% | 94.0% | 87.0% |
| Operating Margin | 43.1% | 43.1% | -53.4% | -38.8% | -471.7% |
| Net Margin | 48.6% | 48.6% | -51.1% | -56.1% | -449.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.05 | 0.02 | 0.02 |
| Current Ratio | 6.23 | 6.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $31.3M | $31.3M | $49.5M | $-36.1M | $-34.6M |
| Returns | |||||
| ROE | 34.4% | 34.4% | -25.9% | -28.6% | -43.4% |
| Valuation | |||||
| P/E | 6.47 | 6.47 | — | — | — |
| EV/EBITDA | 4.50 | 4.50 | — | — | — |
| P/B | 2.25 | 2.25 | 2.61 | 2.34 | 0.97 |
| Growth & Yield | |||||
| Revenue Growth | 161.1% | 161.1% | -16.7% | 346.1% | — |
| EPS Growth | 337.5% | 337.5% | 23.8% | 46.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-16.9%
EPS terminal req.
$0.22
Spread vs growth
354.4%
5Y implied EPS CAGR
-7.0%
EPS terminal req.
$0.26
Spread vs growth
344.5%
10Y implied EPS CAGR
1.1%
EPS terminal req.
$0.43
Spread vs growth
336.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+67.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → 0.38
Residual
+67.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.